ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1709

Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial

Min Jung Kim1, Eun Hye Park2 and Kichul Shin3, 1Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Republic of Korea, 2Chung-Ang University Hospital, Seoul, Republic of Korea, 3Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea

Meeting: ACR Convergence 2021

Keywords: Mesenchymal stem cells, rheumatoid arthritis, Safety

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Mesenchymal stem cell (MSC) therapy represents a promise for the treatment of autoimmune diseases due to its potent immunomodulatory effect. We investigated the long-term safety of a single treatment of human umbilical cord blood-derived (hUCB)-MSCs in patients with rheumatoid arthritis (RA).

Methods: Patients with RA who met the 2010 ACR/EULAR classification criteria and received a single intravenous infusion of hUCB-MSCs (3 groups; 2.5 x 107, 5.0 x 107, 1.0 x 108 cells) in a phase I trial (NCT02221258) entered this 5-year observational study. Safety assessments were carried out at 3, 6, and 12 months for the first year after the hUCB-MSC administration and annually thereafter for the remaining period. Key safety endpoints included overall adverse events (AEs), serious adverse events (SAEs) and AEs of special interest including infection, thromboembolism, and benign/malignant tumor. Physical examination, laboratory tests and electrocardiograms were also performed.

Results: A total of nine patients were treated after the phase I trial at a single center. The most frequent AEs (Table) over 5 years were osteoarthritis (66.7%), nasopharyngitis (44.4%), abdominal pain (33.3%), osteopenia or osteoporosis (33.3%), lumbar spinal stenosis (22.2%), and hypertension (22.2%). SAEs occurred in 5 patients (55.6%); a serious infection (cellulitis) happened in one patient in the 1.0 x 108 group that resolved after treatment. Three years after administration of MSCs, a benign ovarian tumor and a breast adenoma were reported in the 2.5 x 107 and 5.0 x 107 groups, respectively. However, no death, thromboembolism or malignancy occurred during the follow up period. The incidence of AEs increased over time after administration of MSCs, but similar across the dose groups. There were no clinically significant laboratory finding, except for a case of hypertriglyceridemia and a case of anemia.

Conclusion: The long-term safety profile of a single dose of intravenous hUCB-MSC in patients with RA was reasonable and acceptable.


Disclosures: M. Kim, None; E. Park, None; K. Shin, None.

To cite this abstract in AMA style:

Kim M, Park E, Shin K. Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/long-term-safety-of-a-single-infusion-of-human-umbilical-cord-blood-derived-mesenchymal-stem-cell-therapy-in-rheumatoid-arthritis-the-5-year-follow-up-of-the-phase-i-clinical-trial/. Accessed January 31, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-safety-of-a-single-infusion-of-human-umbilical-cord-blood-derived-mesenchymal-stem-cell-therapy-in-rheumatoid-arthritis-the-5-year-follow-up-of-the-phase-i-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences